Anna Perdrix Rosell

Co-Founder at Sixfold Bioscience
  • Claim this Profile
Contact Information
us****@****om
(386) 825-5501
Location
London, UK

Topline Score

Topline score feature will be out soon.

Bio

Generated by
Topline AI

You need to have a working account to view this content.
You need to have a working account to view this content.

Experience

    • United Kingdom
    • Biotechnology Research
    • 1 - 100 Employee
    • Co-Founder
      • Mar 2017 - 6 years 10 months

      Cambridge, United Kingdom Sixfold Bioscience is a venture-backed biotech startup developing next-generation delivery tools for RNA therapeutics (Y Combinator W18, Forbes 30 under 30 in Science & Healthcare 2017 and 2018).

    • United Kingdom
    • Non-profit Organizations
    • 200 - 300 Employee
    • SME leader
      • Feb 2020 - 3 years 11 months

      London, England, United Kingdom Supporting individuals in executive roles in high-growth engineering and technology SMEs to develop their leadership skills.

    • United Kingdom
    • Higher Education
    • 700 & Above Employee
    • Member Of The Board Of Advisors
      • Mar 2019 - 4 years 10 months

      United Kingdom Portabolomics is a large consortium from the University of Newcastle working on cutting-edge synthetic biology at the interface of computational research and biological engineering. Funded by EPSRC (£4.4mn), it aims to build a standardised biological interface with applications in research laboratories and industrial settings.

    • United States
    • Book and Periodical Publishing
    • 700 & Above Employee
    • Forbes 30 Under 30
      • Jan 2018 - 6 years

    • United Kingdom
    • Research Services
    • 700 & Above Employee
    • PhD Candidate
      • 2015 - 2019

      London, United Kingdom Investigating the crosstalk between cancer cells and the tumour microenvironment in breast cancer and melanoma and its role in tumour aggressiveness.

    • United Kingdom
    • Research Services
    • Research Associate
      • Apr 2015 - Sep 2015

      Jeremy Carlton lab Identified a novel membrane-binding activity within an ESCRT-III subunit that is essential for post-mitotic nuclear regeneration.

    • United Kingdom
    • Non-profit Organizations
    • 100 - 200 Employee
    • Research Associate
      • Feb 2014 - Apr 2015

      Andrew Tutt and Anita Grigoriadis labs- Guy's Hospital London -Worked on target identification and validation of two drug targets for triple-negative breast cancer -Analysed gene expression data of germline BRCA1 wild-type and mutated tumours using the statistical R environment.

    • Denmark
    • Non-profit Organization Management
    • 100 - 200 Employee
    • Medical exchange internship
      • Jul 2013 - Aug 2013

      Immunology department, University of Belgrade - Shortlisted as a candidate to attend the IFMSA medical exchanges. - Performed research on experimental autoimmune encephalomyelitis

    • Spain
    • Research Services
    • 300 - 400 Employee
    • Research Assistant
      • Nov 2012 - Jul 2013

      Roger Gomis Lab -Biomarker identification for patients at higher risk of lung metastasis.

    • United Kingdom
    • Biotechnology Research
    • 100 - 200 Employee
    • Research Intern
      • Jul 2012 - Aug 2012

      Oxford, United Kingdom -Worked on identifying the best combination of different promoter and effector sequences in olive fly, Bactrocera oleae, in relation to induction of male sterility.

Education

  • Stanford University Graduate School of Business
    Executive Leadership Development
    2021 - 2021
  • Quantic School of Business and Technology
    Master of Business Administration - MBA
    2020 - 2021
  • Y Combinator
    2018 - 2018
  • King's College London
    Doctor of Philosophy (Ph.D.), Cancer Research
    2015 - 2019
  • Cambridge Judge Business School
    Accelerate programme, Biotech Business Development
    2016 - 2017
  • King's College London
    Master of Research, Translational Cancer Medicine
    2014 - 2015
  • Universitat de Barcelona
    BsC Biomedical Sciences
    2010 - 2014

Community

You need to have a working account to view this content. Click here to join now